Aptevo reports 93% clinical benefit rate in TP53-mutated AML
Aptevo says mipletamig triplet delivered a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.